 HOUSTON, April 27, 2021 PRNewswire -- Soliton, Inc., Nasdaq: SOLY Soliton or the Company, a medical device company with a novel and proprietary platform technology, today announced that the 52-week results from its pivotal cellulite trial have been accepted for an oral presentation at the American Society for Laser Medicine and Surgery Virtual Annual Conference, held May 15-16, 2021. We are honored to present new long-term cellulite data at the ASLMS annual conference. 